Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.

Vann, Kendra R; Pal, Dhananjaya; Smith, Audrey L; Sahar, Namood-E; Krishnaiah, Maddeboina; El-Gamal, Dalia; Kutateladze, Tatiana G

Vann, Kendra R; Pal, Dhananjaya; Smith, Audrey L; Sahar, Namood-E; Krishnaiah, Maddeboina; El-Gamal, Dalia; Kutateladze, Tatiana G.

Afiliação

Vann KR; Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.
Pal D; Molecular Targeted Therapeutics Laboratory, Levine Cancer Institute, Charlotte, NC, USA.
Smith AL; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Sahar NE; Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Krishnaiah M; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
El-Gamal D; Molecular Targeted Therapeutics Laboratory, Levine Cancer Institute, Charlotte, NC, USA.
Kutateladze TG; Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.

Mol Biomed ; 3(1): 2, 2022 Jan 15.

Article em En | MEDLINE | ID: mdl-35031886

Palavras-chave

BRD4; Bromodomain; Bruton's tyrosine kinase; Inhibitor; Mantle cell lymphoma; Phosphatidylinositol-3 kinase

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Mol Biomed Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google